Fundraiser for Vietnam Vet and LLS
"Wine and Design, Raleigh's first and only wine and painting party company, will be holding its second in-house fundraising event on Saturday, November 13th from 6:30pm-8:30pm. The two-hour painting party, being called "An Evening for Tony", will raise funds to support The Leukemia & Lymphoma Society and was inspired by Carrboro resident Lisa Purvis and her father-in-law, Tony Purvis.
Purvis is a woman on a mission and has been supporting and participating in cancer research fundraising events since her father-in-law, Tony Purvis, was diagnosed with melanoma last November. A Vietnam Vet who said he joined the Navy simply because he liked the ocean, Tony Purvis lost his battle with cancer and passed away on September 30th."
Read More: http://www.24-7pressrelease.com/press-release-rss/wine-and-design-to-hon...
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
